Skip to main content Back to Top
Advertisement

11/14/2019

Dexamethasone Sodium Phosphate Injection

Products Affected - Description

    • Dexamethasone Sodium Phosphate injection, AuroMedics, 4 mg/mL, 1 mL vial, 25 count, NDC 55150-0237-01
    • Dexamethasone Sodium Phosphate injection, AuroMedics, 4 mg/mL, 30 mL vial, 25 count, NDC 55150-0239-30
    • Dexamethasone Sodium Phosphate injection, AuroMedics, 4 mg/mL, 5 mL vial, 25 count, NDC 55150-0238-05
    • Dexamethasone Sodium Phosphate injection, Hikma, 4 mg/mL, 5 mL vial, 25 count, NDC 00641-6146-25

Reason for the Shortage

    • American Regent is not marketing dexamethasone sodium phosphate injection at this time.
    • AuroMedics did not provide a reason for the shortage.
    • Fresenius Kabi has dexamethasone sodium phosphate presentations available.
    • Mylan Institutional has dexamethasone injection available.
    • Hikma has dexamethasone injection on shortage due to increased demand.
    • Somerset Therapeutics has 10 mg/mL 1 mL vials available.

Available Products

    • Dexamethasone Sodium Phosphate injection, Fresenius Kabi, 10 mg/mL, 1 mL preservative-free single dose vial, 25 count, NDC 63323-0506-01
    • Dexamethasone Sodium Phosphate injection, Fresenius Kabi, 10 mg/mL, 10 mL multiple dose vial, 10 count, NDC 63323-0516-10
    • Dexamethasone Sodium Phosphate injection, Fresenius Kabi, 4 mg/mL, 1 mL prefilled syringe, 24 count, NDC 76045-0106-10
    • Dexamethasone Sodium Phosphate injection, Fresenius Kabi, 4 mg/mL, 1 mL single dose vial, 25 count, NDC 63323-0165-01
    • Dexamethasone Sodium Phosphate injection, Fresenius Kabi, 4 mg/mL, 30 mL multiple dose vial, 1 count, NDC 63323-0165-30
    • Dexamethasone Sodium Phosphate injection, Fresenius Kabi, 4 mg/mL, 5 mL multiple dose vial, 25 count, NDC 63323-0165-05
    • Dexamethasone Sodium Phosphate injection, Hikma, 10 mg/mL, 1 mL vial, 25 count, NDC 00641-0367-25
    • Dexamethasone Sodium Phosphate injection, Hikma, 4 mg/mL, 1 mL vial, 25 count, NDC 00641-6145-25
    • Dexamethasone Sodium Phosphate injection, Mylan Institutional, 10 mg/mL, 10 mL vial, 10 count, NDC 67457-0420-10
    • Dexamethasone Sodium Phosphate injection, Mylan Institutional, 4 mg/mL, 1 mL vial, 25 count, NDC 67457-0423-12
    • Dexamethasone Sodium Phosphate injection, Mylan Institutional, 4 mg/mL, 30 mL vial, 25 count, NDC 67457-0421-30
    • Dexamethasone Sodium Phosphate injection, Mylan Institutional, 4 mg/mL, 5 mL vial, 25 count, NDC 67457-0422-54
    • Dexamethasone Sodium Phosphate injection, Somerset Therapeutics LLC, 10 mg/mL, 1 mL preservative-free vial, 25 count, NDC 70069-002125

Estimated Resupply Dates

    • AuroMedics has dexamethasone sodium phosphate 4 mg/mL 1 mL, 5 mL, and 30 mL vials on intermittent back order and the company is releasing product as it becomes available.
    • Hikma has dexamethasone sodium phosphate 4 mg/mL 5 mL vials on back order and the company estimates a release date of early-December 2019.

Updated

Updated November 14, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created March 18, 2011 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins